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Introduction 
Expanding from China around the World, COVID-19 is the disease caused by the Severe Acute 
Respiratory Syndrome Related Coronavirus 2 (SARS-CoV-2). COVID-19 primarily manifests by hypoxic 
normo-hypocapnia with preserved lung compliance [1]. In the absence of targeted treatment, sub-
intensive clinicians support patients with non-invasive ventilation and anti-inflammatory/anti-viral 
agents waiting for status improvement. Angiotensin-converting enzyme 2 (ACE2), highly expressed 
on the external membrane of lungs, heart, kidney and gastrointestinal tract cells, displays the 
binding site for the spike protein of SARS-CoV-2 [2]. ACE2, identified as counterpart of the Renin-
Angiotensin-Aldosterone System (RAAS), converts Angiotensin (Ang) II to Ang-(1-7) and Ang I to Ang-
(1-9). ACE2 activity induces vasodilatation and reduces cell growth and inflammatory response. In 
experimental models that mimic the viral acute respiratory distress syndrome (ARDS), the absence 
of Ace2 led to inflammation, vascular permeability and lung injury via activation of Ang II pathway [3, 
4]. The decrease in ACE2 activity by SARS-CoV-2 can unleash a cascade of injurious effects through a 
heightened imbalance in the actions of the products of ACE vs ACE2. Moving to a clinical setting, the 
ACE2 downregulation may be one of the pathways sustaining arterial hypertension [5] and 
pulmonary arterial hypertension [6]. Therefore, it is conceivable that in COVID-19 a cleavage of 
membrane ACE2 along with its circulatory levels could impact on the disease progression and clinical 
worsening [7]. Thus, to support a pathophysiological role of ACE2, the present report shares clinical 
data from an observational study conducted on 40 patients with a diagnosis of COVID-19, 
hospitalized in the Cardiorespiratory Sub-Intensive COVID-19 Unit at the Fondazione IRCCS Ca’ 
Granda Policlinico Hospital of Milan. 
Methods 
Forty consecutive patients with COVID-19 were recruited. At that time, standardized treatment was 
hydroxychloroquine and lopinavir/ritonavir. Blood pressure (BP), partial pressure of oxygen and 
inspiratory fraction of oxygen ratio (PaO2/FiO2) and alveolar-arterial oxygen gradient (A-aO2) were 
measured 2 to 4 times/day according to standard clinical protocol. Median value of plasma 
potassium concentration ([K+]plasma) was also evaluated. In the case of any supplementation of 
potassium, or administration of mineralcorticoid receptor antagonists or diuretic stimulators, the 
[K+]plasma we considered was referred prior to the pharmacological intervention. The relationship 
between respiratory and hemodynamic variables, i.e. A-aO2 vs meanBP was evaluated by Poon’s 
analysis which allows to normalize the inter-individual variability [8]. The composite of death and 
invasive ventilation were evaluated after 28 days of hospitalization. 
Results 
Mean age was 6411 years and twenty-nine out of forty patients were male. All patients had normal 
heart function, but one had stable heart failure with reduced ejection fraction. Despite only 23 
patients presented with a pre-existing history of hypertension (preHT), all patients, although under 
optimized non-invasive ventilatory treatment (optimal FiO2 and positive end-respiratory pressure), 
showed a degradation of PaO2/FiO2 and A-aO2 concomitant with a raised BP and average drop in 
[K+]plasma (figure, Panel A-B-C-D). [K+]plasma median was 3.8 mmol/L. The median time period leading 
to a negative clinical picture was 4.25 days. According to hemodynamic and respiratory changes, 
patients were grouped as follows: group 1 (8/40 patients, 4/8 with preHT) and group 2 (32/40 
patients, 15/32 with preHT). Group 1 showed temporary oscillations towards high BP with contrary 
changes in lung function (best vs worst status: PaO2/FiO2=311 vs 130 mmHg; A-aO2=107 vs 312 
mmHg; meanBP=83 vs 89 mmHg). After 28 days, these patients showed better outcomes, i.e. no 
deaths and clinical improvement, even after the need of invasive ventilatory support (2 cases). 
Patients in group 2 were in critical disease (best status: PaO2/FiO2=286 mmHg; A-aO2=158 mmHg; 
meanBP=88 mmHg). They experienced a rapid deterioration of clinical conditions with linear 
increasing of BP and progressive worsening in gas exchange (worst status: PaO2/FiO2=122 mmHg; 
A-aO2=364 mmHg; meanBP=111 mmHg). Panel E shows a positive correlation between A-aO2 and 
meanBP as assessed by Poon’s analysis (slope= 6.666, R2=0.757; p< 0.0001). According to our 
hypothesis, [K+]plasma was considered as marker of RAAS activation and in group 2 the median value 
of 3.8 mmol/L was used to stratify the patients. The slope of A-aO2/meanBP relationship was 
significantly (U Test, p<0.001) stepper in those with [K+]plasma <3.8 mmol/L (see grey dots of panel F). 
After 28 days, compared to group 1, those in group 2 had a greater prevalence of intensive care 
need (6/32) and a higher mortality (16/32) in a very short period time (6.1 days). At the date of April 
12th, the remaining 10 patients were still alive or discharged at home. 
Discussion 
Our findings showed that in COVID-19 a degradation of lung function may be associated with a rise 
in BP. Though COVID-19 is primarily known as a respiratory disease, it seems to move progressively 
to a vascular disease resulting in a hemodynamic instability. In line with the evidence that SARS-CoV-
2 knocks out the vasodilatory modulation driven by ACE2 [7, 9], we indirectly documented the RAAS 
activation by monitoring [K+]plasma changes. Indeed, there is particular concern about hypokalemia in 
COVID-19, due to interaction of SARS-CoV-2 with RAAS [10]. According to [K+]plasma and BP variability, 
an up-regulation of aldosterone might be one of the fatal mechanisms leading to a negative 
prognosis. Aldosterone which is a potent arteriolar vasoconstrictor directly acts on salt and water 
retention as well as on inflammation [6]. Considering that a raising BP could mirror the systemic 
vasoconstriction due to ACE2 depletion, the increased ventilatory dead space (A-aO2) may be an 
expression of changes in pulmonary vessels tone leading to blood flow redistribution. Indeed, in 
stable condition, hypoxic pulmonary vasoconstriction is physiologically protective allowing a 
perfusion steering blood flow toward functionally preserved lung regions [11]. When COVID-19 
reaches a certain stage, there is a disproportionate endothelial damage that disrupts pulmonary 
vasoregulation, promotes ventilation-perfusion mismatch (the primary cause of initial hypoxemia), 
and fosters thrombogenesis [12]. Overall, our evidence, that has to be further verified suggests that 
COVID-19 patients are less capable to counteract the progressive activation of the RAAS, then the 
Ang II/AT1R axis, via downregulation of ACE2. In group 1 a sort of physiological or pharmacological 
counterbalance restored the best possible status. In group 2, the extreme severity of the disease has 
led to worst outcome. The quicker the hemodynamic changes, the greater the severity of COVID-19 
syndrome. While the results of the trial on recombinant-human-ACE2 are still awaited 
(NCT04335136), COVID-19 patients may benefit from known endothelial active agents, i.e. ACE-
inhibitors, angiotensin II type-I receptor blockers or mineralcorticoid-receptor antagonists.  
Figure legend: 
Box plots of oxygen and inspiratory fraction of oxygen ratio (PaO2/FiO2; panel A), Alveolar- arterial 
oxygen gradient (A-aO2; panel B), meanBP (BPmean; panel C), plasma potassium levels 
([K+]plasma; panel D). Statistical significance was obtained through Mann-Whitney U Test comparing 
“Best status” with “Worst status”. *p<0.001.  
Poon’s analysis of A-aO2/meanBP (panel E; n= 137; slope= 6.666, R2=0.757; p< 0.0001) and Poon’s 
analysis of A-aO2/meanBP according to [K+]plasma stratum (panel F). In panel F grey dots 
represent the group with [K+]plasma  3.8 mmol/L (n= 78; slope= 6.686, R2=0.774; p< 0.0001); white 
dots represent the group with [K+]plasma > 3.8 mmol/L (n= 59; slope= 4.491, R2=0.670; p< 0.0001). 
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